These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32374050)

  • 1. Istaroxime in acute heart failure: the holy grail is at HORIZON?
    Chioncel O; Collins SP; Butler J
    Eur J Heart Fail; 2020 Sep; 22(9):1694-1697. PubMed ID: 32374050
    [No Abstract]   [Full Text] [Related]  

  • 2. Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes.
    Gheorghiade M; Sabbah HN
    Am J Cardiol; 2007 Jan; 99(2A):1A-3A. PubMed ID: 17239700
    [No Abstract]   [Full Text] [Related]  

  • 3. Istaroxime in heart failure new hope or more hype.
    Dec GW
    J Am Coll Cardiol; 2008 Jun; 51(23):2286-8. PubMed ID: 18534277
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
    Gheorghiade M; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Valentini G; Sabbah HN;
    J Am Coll Cardiol; 2008 Jun; 51(23):2276-85. PubMed ID: 18534276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
    Wehrens XH
    Curr Opin Investig Drugs; 2007 Sep; 8(9):769-77. PubMed ID: 17729189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
    Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
    Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
    Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
    Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure.
    Ferrari P; Micheletti R; Valentini G; Bianchi G
    Med Hypotheses; 2007; 68(5):1120-5. PubMed ID: 17113239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
    Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
    Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
    Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
    Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium.
    Wallner M; Khafaga M; Kolesnik E; Vafiadis A; Schwantzer G; Eaton DM; Curcic P; Köstenberger M; Knez I; Rainer PP; Pichler M; Pieske B; Lewinski DV
    Oncotarget; 2017 Jul; 8(30):49264-49274. PubMed ID: 28514771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.
    Lo Giudice P; Mattera GG; Gagnol JP; Borsini F
    Cardiovasc Drugs Ther; 2011 Apr; 25(2):133-8. PubMed ID: 21287411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Istaroxime and Beyond: New Therapeutic Strategies to Specifically Activate SERCA and Treat Heart Failure.
    Avvisato R; Jankauskas SS; Santulli G
    J Pharmacol Exp Ther; 2023 Jan; 384(1):227-230. PubMed ID: 36581352
    [No Abstract]   [Full Text] [Related]  

  • 16. [What is new in the medical management of acute heart failure?].
    Meyer P; White M; Keller RF; Lerch R; Hullin R
    Rev Med Suisse; 2010 Jun; 6(252):1211-7. PubMed ID: 20614757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Istaroxime, a positive inotropic agent devoid of proarrhythmic properties in sensitive chronic atrioventricular block dogs.
    Bossu A; Kostense A; Beekman HDM; Houtman MJC; van der Heyden MAG; Vos MA
    Pharmacol Res; 2018 Jul; 133():132-140. PubMed ID: 29753687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Istaroxime: a new luso-inotropic agent for heart failure.
    Mattera GG; Lo Giudice P; Loi FM; Vanoli E; Gagnol JP; Borsini F; Carminati P
    Am J Cardiol; 2007 Jan; 99(2A):33A-40A. PubMed ID: 17239702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Istaroxime: is the remedy better than the disease?: Editorial to: "Chronic istaroxine improves cardiac function and heart rate variability in cardiomyopathic hamsters" by Pietro Lo Giudice et al.
    Farmakis D; Filippatos G
    Cardiovasc Drugs Ther; 2011 Apr; 25(2):115-7. PubMed ID: 21484265
    [No Abstract]   [Full Text] [Related]  

  • 20. Newer inotropes in pediatric heart failure.
    Hoffman TM
    J Cardiovasc Pharmacol; 2011 Aug; 58(2):121-5. PubMed ID: 21386708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.